Now we need the extra in depth combo trial analysis to find that dystrophin production in the mice then I will be truly excited, cannot be far off. Great time to release positive data. GLTA
Ann: First Patient Dosed in ATL1102 Phase IIb DMD Trial, page-14
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $5.7K | 54.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 178869 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 138249 | 3 |
View Market Depth
| Last trade - 13.03pm 08/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |